USANA Health Sciences (NYSE:USNA) Cut to Buy at StockNews.com

USANA Health Sciences (NYSE:USNAGet Rating) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.

Other research analysts have also recently issued reports about the stock. TheStreet cut shares of USANA Health Sciences from a “b” rating to a “c+” rating in a research report on Wednesday, February 9th. Zacks Investment Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 13th. Finally, DA Davidson assumed coverage on shares of USANA Health Sciences in a research report on Wednesday, April 13th. They issued a “neutral” rating and a $86.00 target price for the company. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $108.33.

Shares of NYSE USNA traded down $3.22 during mid-day trading on Tuesday, reaching $75.52. The company had a trading volume of 69,800 shares, compared to its average volume of 70,238. The firm has a 50 day simple moving average of $82.41 and a two-hundred day simple moving average of $93.07. The stock has a market cap of $1.45 billion, a P/E ratio of 13.23 and a beta of 0.87. USANA Health Sciences has a 52-week low of $75.52 and a 52-week high of $107.85.

USANA Health Sciences (NYSE:USNAGet Rating) last announced its quarterly earnings data on Tuesday, February 8th. The company reported $1.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.30 by ($0.27). The company had revenue of $267.30 million during the quarter, compared to analyst estimates of $273.00 million. USANA Health Sciences had a net margin of 9.82% and a return on equity of 28.84%. During the same quarter last year, the business earned $1.87 EPS. Research analysts predict that USANA Health Sciences will post 5.51 earnings per share for the current fiscal year.

In other news, Director Gilbert A. Fuller sold 312 shares of the company’s stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $89.62, for a total transaction of $27,961.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joshua Foukas sold 3,303 shares of the company’s stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $89.93, for a total value of $297,038.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,653 shares of company stock valued at $600,825. 0.36% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Crew Capital Management Ltd. bought a new stake in USANA Health Sciences during the fourth quarter worth $202,000. UBS Asset Management Americas Inc. grew its position in USANA Health Sciences by 29.4% during the third quarter. UBS Asset Management Americas Inc. now owns 13,284 shares of the company’s stock worth $1,225,000 after buying an additional 3,017 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in USANA Health Sciences by 83.0% during the third quarter. Cubist Systematic Strategies LLC now owns 5,664 shares of the company’s stock worth $522,000 after buying an additional 2,569 shares in the last quarter. Blue Bell Private Wealth Management LLC purchased a new position in USANA Health Sciences during the fourth quarter worth about $101,000. Finally, Martingale Asset Management L P grew its position in USANA Health Sciences by 141.0% during the third quarter. Martingale Asset Management L P now owns 12,785 shares of the company’s stock worth $1,179,000 after buying an additional 7,480 shares in the last quarter. Institutional investors own 54.82% of the company’s stock.

USANA Health Sciences Company Profile (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Read More

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.